- Previous Close
0.00 - Open
90.61 - Bid 51.08 x 36200
- Ask 56.08 x 21500
- Day's Range
90.61 - 90.61 - 52 Week Range
86.05 - 90.61 - Volume
100 - Avg. Volume
0 - Market Cap (intraday)
4.635B - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
28.95 - EPS (TTM)
3.13 - Earnings Date May 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 8, 2024
- 1y Target Est
--
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, aseptic filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
www.rovi.es2,197
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: LABFF
View MorePerformance Overview: LABFF
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LABFF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LABFF
View MoreValuation Measures
Market Cap
2.77B
Enterprise Value
2.87B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
17.92%
Return on Assets (ttm)
13.69%
Return on Equity (ttm)
24.33%
Revenue (ttm)
763.75M
Net Income Avi to Common (ttm)
136.88M
Diluted EPS (ttm)
3.13
Balance Sheet and Cash Flow
Total Cash (mrq)
28.02M
Total Debt/Equity (mrq)
19.67%
Levered Free Cash Flow (ttm)
44.63M